JP6799086B2 - Method for quantifying hydrophobic components in liquid using contact surface diffusion coefficient and method for providing information for diagnosis of diseases using this method - Google Patents

Description

In the present invention, a method for quantifying a hydrophobic component contained in a liquid using the contact surface diffusion coefficient (CADF) of the liquid to a solid surface, specifically, a fat component, and metabolism using the same. It relates to a method for predicting the possibility of developing a sexual disease or dementia, specifically diabetes, fat embolism or dementia, or providing information for diagnosing the onset or course of the above-mentioned disease.

Social costs for dementia are higher than total costs for cancer, heart disease and stroke, and national medical costs for dementia are expected to double every 10 years. According to a report published in the New England Journal of Medicine, a non-profit private research organization, the family and social costs of Alzheimer's and other dementia patients are estimated at about $ 157 billion. The annual cost of treatment is expected to be $ 56,000 per person. Alzheimer's disease, the most common symptom of dementia, currently reaches 5.3 million people in the United States and is known as the sixth cause of death.

However, despite the high cost of treatment for dementia, it is impossible to completely cure dementia at the current level of medical technology, and it is only a temporary relief of the symptoms and delays the progression of the disease. Is also in a difficult state. This is due to a lack of understanding of the clear pathological causes of dementia and the inability to provide personalized treatment for individual patient differences. Personalized treatment begins with the convenience of diagnosing dementia patients and their low cost in daily life, and if this allows individual management, increase the number of dementia patients and increase costs. It can be of great help in preventing it.

Fat embolism is one of the leading causes of death that can occur during surgery, especially liposuction and orthopedic surgery, which have a very high number of surgeries per year, with a low probability of fat embolism. However, the mortality rate at the time of illness is very high, and many fatal accidents occur every year.

According to the statistics officially compiled in the 2009 International Society for Asthetic Plastic Surgery (ISAPS) report, liposuction is the most commonly performed cosmetic surgery out of 21 cosmetic surgeries worldwide. In South Korea, more than 16,000 cases were carried out during the same period.

Liposuction is the most frequently performed cosmetic surgery procedure, but the risks associated with liposuction are not well known to the general public. Fat embolism is caused by the influx of fat into the bloodstream through blood vessels damaged during liposuction, and the influx of fat into the bloodstream severely reduces lung function and other organs. Can also penetrate. Despite its relatively low probability of developing fat embolism, it is known to cause hundreds of fatal accidents worldwide due to its extremely high mortality rate at the time of onset.

In order to prevent fat embolism that may occur during liposuction, the amount of fat that has flowed into the bloodstream before, during, and after the procedure must be measured at any time, and such fat mass is quantified. No device has been developed to date.

The present inventors have described in a prior patent application (Korean patent application No. 10-2012-0147029) a method for measuring the contact surface diffusion coefficient (CADF) of a liquid and the amount of fat permeated into the liquid. There is. The CADF measuring method described in the above prior application measures the degree to which the contact diameter or contact area of the droplet contact surface in contact with the solid plane changes with the lapse of a certain period of time, or measures the degree of change in the fat component present in the liquid. Includes measuring changes in the amount of to obtain CADF.

However, since the CADF measurement method uses only one of the contact diameter and the contact area as a measurement variable, the following practical problems are required to accurately detect the contact surface diffusion coefficient of the liquid. was there.

In particular, if the initial contact surface between the droplet and the solid does not form a circle, or if the outer shape of the contact surface changes irregularly after a certain period of time, the contact surface will come into contact after a certain period of time. There is a problem that the measurement error becomes large when measuring the diameter or the contact area.

Further, when the CADF is measured using only the contact area, the contact between the droplet and the solid is observed in observing the shape of the contact surface above or below the vertical direction of the droplet in order to measure the contact area of the droplet. There was also the problem that the boundary line of the surface could not be identified accurately. Specifically, in the case of a hydrophobic surface in which the contact angle between the droplet and the solid surface is larger than 90 °, the diameter of the droplet measured from either the upper or lower direction is the diameter of the contact surface. Because it is larger, the outer boundary of the droplet hides the boundary of the contact surface, making it difficult to accurately distinguish the boundary of the contact surface.

Even on a hydrophilic surface where the contact angle between the droplet and the solid surface is smaller than 90 °, the boundary between the droplet and the solid surface becomes continuously thin, so observe above or below the solid surface in the vertical direction. In some cases, it was difficult to pinpoint the boundaries.

When CADF is measured using only the contact diameter of the contact surface between the droplet and the solid surface, the shape of the droplet is observed from the side surface to identify both ends of the contact surface, and the distance between both ends is determined by the contact diameter. However, in many cases, the shape of the contact surface is not exactly circular, and the contact surface diffusion coefficient cannot be accurately measured only by such a change in the contact diameter, so that an error occurs.

For the above reasons, in order to achieve the measurement accuracy required to enable actual industrial use, both the contact area and the contact diameter between the droplet and the solid surface are included as variables to ensure the accuracy. An improved method for calculating the contact surface diffusion coefficient was sought.

Therefore, the present inventors include a conventionally known method for calculating the contact surface diffusion coefficient based on the contact area between the droplet and the solid surface and a method for calculating the contact surface diffusion coefficient based on the contact diameter, while maintaining accuracy. We have completed a new calculation method for the contact surface diffusion coefficient with improved.

The present invention is a method for quantifying a hydrophobic component, specifically a fat component, contained in a liquid using the contact surface diffusion coefficient (CADF) of the liquid with respect to a solid surface, and a disease using the method, specifically, cognition. It is an object of the present invention to provide a method for predicting the possibility of developing a disease, diabetes or fat embolism, and providing information for diagnosing the onset or course of the above-mentioned diseases.

The method for quantifying the hydrophobic component contained in the liquid according to the embodiment of the present invention is as follows: a) The liquid droplets are brought into contact with the solid surface, and the initial area of the contact surface between the droplets and the solid surface (A _0). ) and measuring a initial diameter (d ₀₎ of the contact surface, b) after a predetermined time (t) has elapsed, the area of the contact surface between the droplet and the solid surface (a _t) and the Provided is a method including a step of measuring the diameter ( _dt ) of the contact surface and a step of c) obtaining a contact surface diffusion coefficient (CADF) based on the following formula 1.

(In the above equation, n, m, N and M are constants.)

According to one embodiment of the present invention, the method for quantifying the hydrophobic component contained in the liquid is as follows: d) The content of the hydrophobic component contained in the droplet using the contact surface diffusion coefficient and the following formula 2. May further include the step of obtaining.

(In the above equation, k, C ₀ , A, B, D, P and Q are correction constants.)

According to one embodiment of the present invention, the liquid may be a body fluid.

According to one embodiment of the present invention, the body fluid may be selected from the group consisting of blood, serum, plasma, sweat and urine.

According to one embodiment of the present invention, the hydrophobic component may be fat.

The method for predicting the possibility of developing a metabolic disease or dementia or providing information on the onset or course of a metabolic disease or dementia according to an embodiment of the present invention is as follows: a) Droplets of body fluid to be judged are placed on a solid surface. A step of making contact and measuring the initial area (A ₀ ) of the contact surface between the droplet and the solid surface and the initial diameter (d ₀ ) of the contact surface, and b) after a predetermined time (t) has elapsed. , and measuring the droplet and the area of the contact surface between the solid surface (a _t) and the contact surface diameter (d _t), the contact surface diffusion coefficient based on c) the following equation 1 (CADF) The step of obtaining, d) the step of obtaining the content of the fat component contained in the droplet using the contact surface diffusion coefficient and the following formula 2, and e) the step of obtaining the content of the obtained fat component in a normal person. Provided are a step of comparing with the content of a fat component obtained from the body fluid of the body, and a method including.

(In the above equation, n, m, N, and M are constants.)

(In the above equation, k, C ₀ , A, B, D, P and Q are correction constants.)

According to one embodiment of the present invention, when the difference between the content of the fat component obtained from the body fluid to be judged and the content of the fat component obtained from the body fluid of a normal person is a positive number, a metabolic disease or The likelihood of developing dementia is high, or the onset of metabolic or dementia can be diagnosed.

According to one embodiment of the present invention, the body fluid may be selected from the group consisting of blood, serum, plasma, sweat or urine.

According to one embodiment of the present invention, the disease may be selected from the group consisting of dementia, diabetes and fat embolism.

According to one embodiment of the present invention, the dementia may be selected from the group consisting of Alzheimer's disease, Parkinson's disease, vascular dementia, mixed dementia and mild cognitive impairment.

By utilizing the method for quantifying the hydrophobic component contained in the liquid according to the present invention, the content of the fat component contained in the body fluid can be further increased by using the body fluid such as urine which can be obtained cheaply and conveniently from the test object. It can be measured accurately and easily.

In particular, the quantification method according to the present invention improves the measurement accuracy of CADF by simultaneously using the contact area and the contact diameter of the droplet and the solid surface as variables, and only one of the contact area and the contact diameter is used. The likelihood of measurement errors caused by its use can be significantly reduced.

Three types of surface tensions acting along the contact boundary between the droplet and the solid surface were shown. The graph which compares the CADF value of the urine before the liposuction operation (without fat component) and after (including fat component) is shown. The CADF value of the urine sample calculated every 0.5 days after liposuction was shown. It is a graph which shows the relationship between the concentration of a fat component and CADF obtained by diluting a urine sample containing a fat component after liposuction stepwise with ultrapure water and changing the fat content concentration. It is a graph which corrected the total fatty acid concentration and the CADF measurement value measured by gas chromatography (GC), found the fatty acid concentration conversion formula, and compared it. It is a graph which compared the LDL value and the CADF value among the fat components in a blood sample. It is a graph which measured and compared the content of the fat component in the urine of a normal person and the patient of 6 diseases by the GC method and the CADF method by one Example of this invention. At this time, the above six diseases are diabetes (DM), Alzheimer's disease (AD), Parkinson's disease (PDD), vascular dementia (VD), mixed dementia (VD + AD), and mild cognitive impairment (MCI). An apparatus for measuring the concentration of a hydrophobic component contained in a liquid according to an embodiment of the present invention is shown.

Hereinafter, embodiments according to the present invention will be described in detail with reference to the accompanying drawings. The following description is for facilitating understanding of embodiments of the present invention and is not intended to limit the scope of protection.

In the method for quantifying the hydrophobic component contained in the liquid according to the embodiment of the present invention, the contact surface diffusion coefficient (CADF) that appears when the liquid droplets come into contact with the solid surface is calculated, and the liquid is made based on this. Provided is a method for quantifying a hydrophobic component contained, for example, a fat component.

The measurement principle is as follows.

As shown in FIG. 1, γ _gl is the surface tension between a gas and a liquid, γ _ls is the surface tension between a liquid and a solid surface, and γ _gs is the surface tension between a gas and a solid surface. Further, α is the contact angle of the droplet with respect to the solid surface, and d is the contact diameter between the droplet and the solid surface.

When the droplets come into contact with the solid surface, the three surface tensions are balanced against each other. With the passage of time, volatile components such as water may evaporate from the droplets, so that the volume of the droplets decreases and the contact area with the solid surface also decreases. Therefore, the contact area of the droplets in contact with the solid surface becomes constant or decreases over time, and the contact area hardly increases.

However, if the above-mentioned three surface tensions are out of balance, the contact area may be expanded. An example of such is an aqueous droplet containing a fat component in a liquid. The fat component is generally immiscible with water, but in small amounts it can be uniformly mixed with water. Some fats may be dissolved in water in small amounts and can be colloidally and stably mixed with water. When fat is dissolved in an aqueous fluid, if the fluid is brought into contact with the solid surface in the form of droplets, the oil component may adhere to the surface of the solid and the balance of the above-mentioned three surface tensions may be lost.

The surface tension of water is generally stronger than the surface tension of hydrophobic or lipophilic substances. Therefore, when the hydrophobic component dissolved in the aqueous fluid adheres to the solid surface, the balance of the three surface tensions may be lost and the contact area of the droplet may increase. The amount of hydrophobic components, such as fat, that adhere to the solid surface is proportional to the fat concentration in the aqueous fluid and the surface adsorptivity.

When an aqueous droplet containing fat, which is a hydrophobic component, is brought into contact with a hydrophobic surface, the fat component hardly adheres to the solid surface at the initial stage, but over time, hydrophobic substances such as fat become hydrophobic. Adhesion to the surface of a solid solid changes the surface tension between the droplet and the surface of the solid, which causes a contact area diffusion (CAD) phenomenon between the droplet and the surface of the solid.

The method for quantifying the hydrophobic component contained in the liquid according to the embodiment of the present invention includes the following steps of calculating CADF.

a) A step of bringing a liquid droplet into contact with a solid surface and measuring the initial area (A ₀ ) of the contact surface between the droplet and the solid surface and the initial diameter (d ₀ ) of the contact surface.
b) after a predetermined time (t) has elapsed, and measuring the droplet and the area of the contact surface between the solid surface (of A _t) and the contact surface diameter (d _t),
c) A step of obtaining a contact surface diffusion coefficient (CADF) based on the following equation 1.

In the above equation, n, m, N, and M are constants.

The above formula 1 is a calculation formula of the dimensionless form CADF. Here, A _t is the contact area of the droplet after a predetermined time (t) has elapsed, A ₀ is the initial contact area. d _t is the contact diameter of the droplet after a predetermined time (t) has elapsed, and d ₀ means the initial contact diameter.

In the above equation 1, the constants n and m are determined according to the contact area of the contact surface diffusion coefficient and the sensitivity to the diameter of the contact surface, respectively, and the constants N and M are the rate of change of the contact area and the contact diameter, respectively. Determined based on the specific gravity of the rate of change with respect to the contact surface diffusion coefficient. Each constant can be changed according to the measurement environment of the contact surface diffusion coefficient.

The higher the content (concentration) of the hydrophobic component contained in the droplet, for example, the fat component, the larger the contact surface diffusion coefficient. Therefore, the contact surface diffusion coefficient according to one embodiment of the present invention is used to determine the fat component. It is possible to quantify the content. The method for quantifying the hydrophobic component contained in the liquid using the obtained contact surface diffusion coefficient may further perform the following content calculation step.

d) A step of obtaining the content of the hydrophobic component contained in the droplet using the contact surface diffusion coefficient and the following formula 2.

In the above equation, k, C ₀ , A, B, D, P and Q are correction constants. The correction constants are determined to minimize the error through comparative correction based on the measured data of the contents of CADF and the fat component, respectively.

As used herein, "liquid" means a substance that has a volume to be measured but is not fixed in shape. The liquid may be a body fluid existing in the body of an animal such as a human. As used herein, "body fluid" means, but is not limited to, human or animal blood, serum, plasma, sweat, urine, and the like.

As used herein, the "hydrophobic component" or "lipophilic component" means a component having a low affinity for water and having no polarity. The hydrophobic component may be a component that is not volatilized in the air and affects the characteristics of the liquid such as surface tension. The hydrophobic component may be fat.

As used herein, "fat (ingredient)" includes all solid fats, liquid fats, fatty acids and the like. For example, the solid or liquid fats include, but are not limited to, fatty acid triglycerides naturally occurring from vegetable or animal fats, rearranged or randomized fats, transesterified fats. Absent. For example, the fatty acids include saturated or unsaturated (mono-, di- or poly-unsaturated) carboxylic acids containing 10 to 22, for example 12 to 24 carbon atoms. For example, the saturated fatty acids include capric acid, lauric acid, myristic acid, palmitic acid, stearic acid or behenic acid, and the unsaturated fatty acids include oleic acid, linoleic acid or erucic acid, but are limited thereto. is not.

As used herein, "trans fat" means unsaturated fat containing trans fatty acids. Trans fats increase LDL cholesterol in the body and lower HDL cholesterol in the blood. As used herein, "trans fatty acid" means a fatty acid commonly produced by partial hydrogenation of unsaturated fatty acid vegetable oils. At this time, the term "trans" indicates the position where hydrogen atoms are present in opposition when the unsaturated fat is partially hydrogenated.

As used herein, "solid" means a solid having a certain number of parallel planes on which droplets can be placed. The solid may be a hydrophobic or water repellent solid, such as Teflon®, but is not limited thereto. Since hydrophobic components such as fat adhere well to the hydrophobic surface, the CADF measurement sensitivity can be greatly increased. For example, in one embodiment of the present invention, when a Teflon (registered trademark) plate is used as a solid, a detection resolution of up to 1 ppm can be obtained.

As used herein, "contact area of the droplet _{(A 0,} A _t)" means the area of a portion where the surface of the droplet and the solid is in direct contact. The contact area of the droplet is determined by utilizing a sensor provided on the surface of the solid, or after photographing the contact surface between the droplet and the surface of the solid in one direction, for example, the lower surface of the solid. It may be measured through a method such as calculating the area of, but is not limited to this.

As used herein, the "droplet contact diameter (d ₀ , _dt )" means the length of the portion where the droplet and the surface of the solid are in direct contact with each other when observed in any direction. The contact diameter of the droplet is the length of the contact diameter after utilizing a sensor provided on the surface of the solid or after photographing the contact surface between the droplet and the surface of the solid in one direction, for example, a side surface. It may be measured through a method such as calculating the diameter, but the present invention is not limited to this.

As used herein, "contact angle (α)" means the angle formed between the surface of a solid and the line tangent to the radius of the droplet from the point of contact between the solid.

As used herein, the "predetermined time (t)" is the time sufficient for the contact area diffusion (CAD) phenomenon to occur between the droplet and the solid surface, eg, 5 minutes to 1 hour. For example, it may be 10 to 30 minutes, for example, 20 minutes. The predetermined time (t) may be adjusted according to measurement conditions such as fat concentration, temperature and humidity.

FIG. 2 shows the CADF value of urine before and after the liposuction operation (without fat component) and after that (including fat component). The horizontal axis shows the elapsed time (minutes), and the vertical axis shows the CADF value.

As shown in FIG. 2, depending on the fat content in urine, the CADF value is negative when the urine does not contain a fat component, and CADF when the urine contains a fat component. The value is indicated by a positive number. It can be seen that this can be used to detect the content of the fat component contained in the liquid.

The CADF value of fat-free urine is measured negatively. That is, since the contact angle is maintained, the contact area and / or contact diameter of the fat-free urine droplets decreases as the water evaporates. In contrast, the CADF value of fat-containing urine is measured as a positive number. That is, after a predetermined time has elapsed, the contact area and / or contact diameter of the droplet is enlarged from that of the initial droplet.

FIG. 3 shows the CADF of urine samples collected every 0.5 days after liposuction. CADF per sample was measured 4 times to calculate mean and standard deviation.

According to FIG. 3, the CADF of the urine sample collected 2.5 days after the liposuction operation was the largest, and became a negative number 3.5 days later. This is in good agreement with the fact that patients undergoing liposuction recover on average after 3 days. In addition, it is well shown that the measurement sensitivity to the fatty acid content contained in urine is so high that the influence of medical treatment such as compression bandage and infusion appears in the CADF value.

FIG. 4 shows the relationship between the concentration of the fat component and CADF obtained by diluting the urine sample containing the fat component stepwise with ultrapure water after the liposuction treatment and changing the fat content concentration.

Fat-containing urine samples collected from patients undergoing liposuction were diluted with ultrapure water to prepare relative concentrations from 100% (pure urine) to 0.4%. It was confirmed that CADF also decreased as the relative concentration decreased, showing a monotonous proportional relationship. This makes it possible to confirm that CADF can be used to quantify fat concentration.

FIG. 5 shows a graph in which the fatty acid concentration conversion formula was obtained by correcting the total fatty acid concentration and the CADF measurement value measured by gas chromatography (GC) and comparing them.

Considering that CADF according to one embodiment measures the change in surface energy due to fat adsorption on the solid surface, the concentrations of CADF and the fat component are in a monotonous proportional relationship. Therefore, the concentration of fat content is mathematically expressed using a monotonic function such as an exponential function, a linear function, or a logarithmic function as shown in Equation 2 below.

The fat concentration value measured by the GC method is applied to Equation 2 to determine the correction coefficient, which can be expressed by a simple monotonous increase exponential function as shown in Equation 3 below.

Through the CADF value measured by the CADF measurement method according to one example and Equation 3, the fat content of the aqueous fluid can be quantified as in the GC measurement method. However, the correction constant value used in Equation 2 is not limited to the correction constant used in Equation 3.

In one example, the absolute concentration of fat in a fat-containing urine sample collected from a patient who underwent liposuction by gas chromatography (GC) analysis was measured, CADF was measured for the same sample, and then compared. The correction coefficient of the above equation 2 was determined through the correction, and the results were shown in FIG. 5 for comparison. The formula for C _CADF can be obtained based on the GC analysis value as follows: correction constants A are 2.03, P is 3.65, Q is 5.53, D is 10, and k, C ₀ and B decided to 0.

FIG. 6 shows the correlation between the low-density lipoprotein (LDL) value and the CADF value among the fat components in the blood sample. This shows that the LDL value is proportional to CADF, but the high density lipoprotein (HDL) value is not correlated with CADF. This indicates that the CADF according to one embodiment can be measured more sensitively to saturated fat and trans fat that adhere more well to the blood vessel wall and the like.

Another embodiment of the present invention utilizes the method for quantifying the hydrophobic component contained in the liquid according to the above-mentioned embodiment, predicting the possibility of developing a metabolic disease or dementia, or a metabolic disease or dementia. Provide a method of providing information on the onset or course of dementia.

Specifically, the method for predicting the possibility of developing a metabolic disease or dementia or providing information on the onset or course of a metabolic disease or dementia may include the following steps.

a) A step of bringing a droplet of a body fluid to be judged into contact with a solid surface and measuring the initial area (A ₀ ) of the contact surface between the droplet and the solid surface and the initial diameter (d ₀ ) of the contact surface. ,
b) after a predetermined time (t) has elapsed, and measuring the droplet and the area of the contact surface between the solid surface (of A _t) and the contact surface diameter (d _t),
c) At the stage of obtaining the contact surface diffusion coefficient (CADF) based on the following equation 1

(In the above equation, n, m, N, and M are constants.)
d) A step of obtaining the content of the fat component contained in the droplet using the contact surface diffusion coefficient and the following formula 2 and

(In the above equation, k, C ₀ , A, B, D, P and Q are correction constants.)
e) A step of comparing the content of the obtained fat component with the content of the fat component obtained from the body fluid of a normal person.

If the difference between the content of the fat component obtained from the body fluid to be judged and the content of the fat component obtained from the body fluid of a normal person is a positive number, there is a high possibility of developing a metabolic disease or dementia. Or the onset or course of metabolic disease or dementia can be diagnosed.

As used herein, "metabolic disorders" include obesity, non-alcoholic liver disease, glucose tolerance disorders, hyperinsulinemia, hyperglycemia, diabetes, hypertension, arteriosclerosis, hyperlipidemia or fat embolism. Including, preferably, diabetes or fat embolism can be, but is not limited to.

As used herein, "dementia" includes, but is not limited to, Alzheimer's disease, Parkinson's disease, vascular dementia, mixed dementia, and mild cognitive impairment.

FIG. 7 shows six diseases: diabetes (DM), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), vascular dementia (VD), mild cognitive impairment (MCI) and mixed dementia ( The results of a preclinical study of free fatty acids in urine measured by the GC method and the CADF method according to one example were shown for 400 patients suffering from AD + VD) and 100 normal persons.

According to FIG. 7, it was confirmed that the content of the fat component contained in the urine of each patient was much higher than that of the normal person, and it was found that the measurement results of GC and CADF all showed very similar results. ..

In particular, in the case of urine of dementia patients such as Alzheimer's disease (AD) and Parkinson's disease (PDD), the value is almost twice as high as that of a normal person, and the diagnosis of the CADF method of the present invention for these diseases is shown. It was confirmed that the reliability was high.

Moreover, since the fatty acid value of a diabetic patient is lower than that of a dementia patient but still higher than that of a normal person, the CADF method of the present invention can be used as a diabetic diagnosis method. In the case of diabetes, if the method according to one embodiment of the present invention is used, it is possible to greatly contribute to individual diabetes management by continuing to perform diagnostic management conveniently at a low cost using a urine sample, and it is difficult to collect blood. It can also be very useful for blood glucose control in diabetic patients.

The method for quantifying fat components using the CADF method according to one example enables diagnosis of dementia by measuring the fatty acid content in a body fluid that is easily available such as urine. Therefore, the effects of implementing various treatment methods for dementia can be easily compared with each other, and through this, the optimal treatment method for each individual can be found.

Using the method according to one example, diabetes can be diagnosed or managed by measuring the fat content of readily available body fluids such as urine. Therefore, the effects of various diabetes treatment methods can be easily compared with each other, and an individual optimal diabetes treatment method can be found.

Using the method according to one example, fat embolism can be diagnosed and prevented by measuring the content of fat components flowing into blood or urine before, during, or after liposuction. To do so. Therefore, appropriate medical measures can be taken for the patient before the onset of fat embolism.

The method of measuring CADF according to one embodiment can be applied to a quantitative analysis technique, for example, a method of measuring the amount of fat contained in a sample. Compared to GC, the CADF method of the present invention is cheaper, faster and more convenient.

To supplement conventional analytical techniques such as GC, the CADF measurement method of the present invention may be combined with conventional analytical techniques. For example, the CADF measurement results according to the present invention can be applied to fat analysis that cannot be directly measured by UV or fluorescence spectroscopy.

The CADF method according to one embodiment can be applied to personalized body fat management in the fields of health care, diet and obesity.

Yet another embodiment of the present invention provides an apparatus for quantifying the hydrophobic component contained in the liquid by utilizing the method for quantifying the hydrophobic component contained in the liquid according to the above one embodiment.

FIG. 8 shows a device for measuring the concentration of hydrophobic components contained in a liquid according to an embodiment of the present invention.

Referring to FIG. 8, the concentration measuring device 100 for the hydrophobic component contained in the liquid includes a measuring unit 110, a calculation unit 120, and an output unit 130. Each component of the concentration measuring device 100 may be embodied in a computing device or may be embodied in another device that operates in conjunction with the computing device.

The measuring unit 110 is configured to obtain a numerical value of the contact area or contact diameter of the liquid droplet and the contact surface of the solid surface with respect to the contact surface. The measuring unit 110 may include a solid having a certain number of parallel planes on which droplets can be placed.

The measuring unit 110 includes an imaging device capable of acquiring images for droplets and solids for numerical calculation of the contact area or contact diameter, for example, a CCD (Charge-Coupled Device) camera, an optical sensor, and the like. Alternatively, the touch sensor provided on the above individual may be included, but is not limited thereto. The measuring unit 110 can also simultaneously measure the contact area or contact diameter of one or more droplets placed on the individual. The measuring unit 110 can measure a numerical value of a different contact area or contact diameter with the passage of time for one droplet.

The measuring unit 110 may include a control unit of the imaging device capable of adjusting the position, focus, etc. of the imaging device, and a memory in which the acquired numerical value of the contact area or contact diameter is stored in the memory, if necessary. Good.

The calculation unit 120 obtains a contact surface diffusion coefficient (CADF) based on the following equation 1 using the acquired numerical values of the contact area or contact diameter, and obtains the obtained contact surface diffusion coefficient (CADF) and the following. It can be obtained by calculating the content of the hydrophobic component contained in the droplet using the formula 2.

In the above equation, n, m, N, and M are constants.

In the above equation, k, C ₀ , A, B, D, P and Q are correction constants.

The calculation unit 120 determines the concentration of the hydrophobic component in the liquid from the obtained determination target based on the concentration data of the hydrophobic component in the liquid obtained from a normal person, for example, a body fluid. By comparison, it is possible to obtain information on the possibility of developing a metabolic disease or dementia to be judged, the presence or absence of the disease, or the course of the disease.

The output unit 130 can display the concentration of a hydrophobic component, for example, a fat component contained in the liquid obtained through the above configuration. Alternatively, the output unit 130 can display a prediction result of the possibility of developing a metabolic disease or dementia in a judgment target based on the concentration of the obtained hydrophobic component, or whether or not the metabolic disease or dementia has developed. Information on the course of onset can also be displayed.

In the above, the present invention has been described focusing on preferable examples. Those who have ordinary knowledge in the technical field to which the present invention belongs will understand that the present invention is embodied in a modified form within a range that does not deviate from the essential characteristics of the present invention. Therefore, the disclosed examples should be considered from a descriptive point of view, not from a limiting point of view. The scope of the present invention is shown by the appended claims, rather than the detailed description described above, and the meaning and scope of the claims, and all modified or modified forms derived from the concept of equality thereof. It should be interpreted as being included in the scope of the invention.

Claims (6)

a) A step of bringing a droplet of body fluid into contact with a solid surface and measuring the initial area (A ₀ ) of the contact surface between the droplet and the solid surface and the initial diameter (d ₀ ) of the contact surface.
b) after a predetermined time (t) has elapsed, and measuring the droplet and the area of the contact surface between the solid surface (of A _t) and the contact surface diameter (d _t),
c) At the stage of obtaining the contact surface diffusion coefficient (CADF) based on the following equation 1
(In the above equation, n, m, N and M are constants.)
d) A step of obtaining the content of fat contained in the droplet using the contact surface diffusion coefficient and the following formula 2 and
(In the above equation, k, C ₀ , A, B, D, P and Q are correction constants.)
A method for quantifying fat contained in a body fluid, which comprises. The method for quantifying fat contained in a body fluid according to claim 1, wherein the body fluid is selected from the group consisting of blood, serum, plasma, sweat and urine. a) A step of bringing a droplet of a body fluid to be judged into contact with a solid surface and measuring the initial area (A ₀ ) of the contact surface between the droplet and the solid surface and the initial diameter (d ₀ ) of the contact surface. ,
b) after a predetermined time (t) has elapsed, and measuring the droplet and the area of the contact surface between the solid surface (of A _t) and the contact surface diameter (d _t),
c) At the stage of obtaining the contact surface diffusion coefficient (CADF) based on the following equation 1
(In the above equation, n, m, N, and M are constants.)
d) A step of obtaining the content of the fat component contained in the droplet using the contact surface diffusion coefficient and the following formula 2 and
(In the above equation, k, C ₀ , A, B, D, P and Q are correction constants.)
e) At the stage of comparing the content of the obtained fat component with the content of the fat component obtained from the body fluid of a normal person,
A method of providing information on the prevention of metabolic diseases or dementia or the onset or course of metabolic diseases or dementia, which comprises. The prevention of metabolic disease or dementia according to claim 3 , or the onset or course of metabolic disease or dementia, wherein the body fluid is selected from the group consisting of blood, serum, plasma, sweat or urine. Information provision method. Information on the prevention of metabolic disease or dementia or the onset or course of metabolic disease or dementia according to claim 3 , wherein the metabolic disease is selected from the group consisting of diabetes and fat embolism. How to provide. The prevention or prevention of metabolic disease or dementia according to claim 3 , wherein the dementia is selected from the group consisting of Alzheimer's disease, Parkinson's disease, vascular dementia, mixed dementia and mild cognitive impairment. How to provide information on the onset or course of metabolic disease or dementia.